FDA approves Keytruda/Padcev combo in advanced urothelial cancer — Record growth in U.S. life sciences real estate footprint — Diabesity drugs and their free ‘contract sales force’ -- See more on our front page news http://bit.ly/w28kSd #fda #merck #astellas #urothelialcancer #realestate #diabetes #obesity #novonordisk #elililly #keytruda #lifesciences #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

RT @TumorBoardTues
#TumorBoardTuesday
👉🏽#CME🔗 http://integrityce.com/tbt

📊One way #TumorBoardTuesday gathers input is with polls, so before @arkhaki @glovedoc take us through treating early progression of #UrothelialCancer be sure to tick your box‼️

👉🏽Tell us where you are in your🩺journey

👇🏽👇🏽👇🏽

Thank you 🙏🏼for a reflective & useful #TumorBoardTuesday!! #UrothelialCancer

💙Lookout for Case Wrap Up🎀Thursday 02/16/22

📅Please join us 𝑇uesday at 8pm ET when @NarjustFlorezMD @ShrutiPatelMD join us to chat I/O + chemo #LCSM

RT @TumorBoardTues
#PreTest Q2️⃣ #CME #TumorBoardTuesday
👉🏽CME Eval 🔗 http://integrityce.com/tbtEval
👉🏽ALL CME🔗 http://integrityce.com/tbt

🤔Which of the following criteria would prevent a patient with #Urothelialcancer from receiving platinum based chemotherapy?

📢We’re here on this #ValentinesDay #TumorBoardTuesday!!

🥼@arkhaki @glovedoc teach us about treating early progression in #UrothelialCancer
👇🏽👇🏽

📱Weigh in your answers
🧾Bring receipts
🙋Ask Q’s
📊check polls
🔁RT
👩🏽‍⚕️tag peers
@MPishvaian @JohnEbbenMDPhD
#MedTwitter #MedEd
---
RT @glovedoc
@TumorBoardTues @TomJayram @arnabguonc @UroCancerMD @vinay_onc @simon_p_kim @AlexAlvaro_PSC @AlyaShamsan @MichaelStaehler @DrOmarMian @kaydaustin @josi…
https://twitter.com/glovedoc/status/1625661196899696643

💙We hear there's an #ASCO23 deadline tonight, but there's always time for #TumorBoardTuesday!

💙1 hour countdown!!

💙@arkhaki @glovedoc take us through early progression of #UrothelialCancer

💙Brew coffee & prepare your 🧠with these #CME👇🏽See you soon!

---
RT @TumorBoardTues
#PreTest Q1️⃣ #TumorBoardTuesday
Free #CME🔗http://integrityce.com/tbt

👉Before @arkhaki & @glovedoc🗣️mgmt of #Urothelialcancer, test your 🧠with these❓s

🤔What …
https://twitter.com/TumorBoardTues/status/1625554522838863883

#PreTest Q2️⃣ #CME #TumorBoardTuesday
👉🏽CME Eval 🔗 http://integrityce.com/tbtEval
👉🏽ALL CME🔗 http://integrityce.com/tbt

🤔Which of the following criteria would prevent a patient with #Urothelialcancer from receiving platinum based chemotherapy?

#PreTest Q1️⃣ #TumorBoardTuesday
Free #CME🔗http://integrityce.com/tbt

👉Before @arkhaki & @glovedoc🗣️mgmt of #Urothelialcancer, test your 🧠with these❓s

🤔What is your 1st line Tx for a 56yo👩w/ mUC who is NOT eligible for platinum-containing therapy❓

RT @TumorBoardTues
Forget the #SuperBowl
💙Set a ⏲ to join #TumorBoardTuesday

👨🏽‍⚕️@arkhaki @glovedoc👨🏻‍⚕️lead us through a #ValentinesDay convo on met #UrothelialCancer with early progression

📅Tues 02.14.23 at 8pm ET

Earn FREE #CME (AMA & MOC)

👉🏽http://integrityce.com/tbt 👈🏼#OncTwitter #BladderCancer

#TumorBoardTuesday
👉🏽#CME🔗 http://integrityce.com/tbt

📊One way #TumorBoardTuesday gathers input is with polls, so before @arkhaki @glovedoc take us through treating early progression of #UrothelialCancer be sure to tick your box‼️

👉🏽Tell us where you are in your🩺journey

👇🏽👇🏽👇🏽

Forget the #SuperBowl
💙Set a ⏲ to join #TumorBoardTuesday

👨🏽‍⚕️@arkhaki @glovedoc👨🏻‍⚕️lead us through a #ValentinesDay convo on met #UrothelialCancer with early progression

📅Tues 02.14.23 at 8pm ET

Earn FREE #CME (AMA & MOC)

👉🏽http://integrityce.com/tbt 👈🏼#OncTwitter #BladderCancer

RT @TumorBoardTues
1/5 #TumorBoardTuesday

🔬🧬A discussion on FGFR alterations in metastatic #UrothelialCancer led by @PGrivasMDPhD @rafee_talukder

➡️Here’s the Thursday Case 🎀

👉🆓 #CME credit by answering 2 quick ❓
ALL CME 🔗: http://integrityce.com/tbt

CME eval🔗: http://integrityce.com/tbteval

RT @TumorBoardTues
1/5 #TumorBoardTuesday

🔬🧬A discussion on FGFR alterations in metastatic #UrothelialCancer led by @PGrivasMDPhD @rafee_talukder

➡️Here’s the Thursday Case 🎀

👉🆓 #CME credit by answering 2 quick ❓
ALL CME 🔗: http://integrityce.com/tbt

CME eval🔗: http://integrityce.com/tbteval

1/5 #TumorBoardTuesday

🔬🧬A discussion on FGFR alterations in metastatic #UrothelialCancer led by @PGrivasMDPhD @rafee_talukder

➡️Here’s the Thursday Case 🎀

👉🆓 #CME credit by answering 2 quick ❓
ALL CME 🔗: http://integrityce.com/tbt

CME eval🔗: http://integrityce.com/tbteval

RT @rafee_talukder
@TumorBoardTues @PGrivasMDPhD @MPishvaian @JohnEbbenMDPhD 3/19 #TumorBoardTuesday @PGrivasMDPhD @MPishvaian @JohnEbbenMDPhD #UrothelialCancer

🤔 Is the above 74yo 🧓🏼 patient a good candidate for platinum-based chemotherapy?

🤨 Poll: Which of these criteria would make this patient platinum-ineligible?

RT @rafee_talukder
@TumorBoardTues @PGrivasMDPhD @MPishvaian @JohnEbbenMDPhD @MattGalsky @DrRosenbergMSK @JonAnker1 5/19 #TumorBoardTuesday
👨🏽‍🏫Mini tweetorial 2👨🏻‍🏫
✨KEYNOTE 052✨

Ph2: Cis-ineligible met #UrothelialCancer who have NOT initiated 1L systemic therapy.
📚https://ascopubs.org/doi/10.1200/JCO.2021.39.15_suppl.4508

Pembro: ONLY immune checkpoint inhibitor approved as 1L in plat-ineligible
📚https://ascopost.com/issues/september-25-2021/fda-revises-label-for-pembrolizumab-in-patients-with-advanced-urothelial-carcinoma/

RT @rafee_talukder
@TumorBoardTues @PGrivasMDPhD @MPishvaian @JohnEbbenMDPhD @MattGalsky @DrRosenbergMSK @JonAnker1 6/19 #TumorBoardTuesday

What thresholds should be used to define platinum ineligibility in #UrothelialCancer?
@shilpaonc Defining platinum-ineligible in patients with metastatic urothelial cancer
📚https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.4577

RT @rafee_talukder
@TumorBoardTues @PGrivasMDPhD @MPishvaian @JohnEbbenMDPhD @MattGalsky @DrRosenbergMSK @JonAnker1 @shilpaonc 8/19 #TumorBoardTuesday #UrothelialCancer

🧓🏼started 1st line pembrolizumab (and zometa for bone mets)

💉 Completed 8 cycles
🩻 Restaging CT: progression of 🫁 mets and retroperitoneal lymphadenopathy

🤨 What 2L treatment do you recommend next?

RT @rafee_talukder
@TumorBoardTues @PGrivasMDPhD @MPishvaian @JohnEbbenMDPhD 3/19 #TumorBoardTuesday @PGrivasMDPhD @MPishvaian @JohnEbbenMDPhD #UrothelialCancer

🤔 Is the above 74yo 🧓🏼 patient a good candidate for platinum-based chemotherapy?

🤨 Poll: Which of these criteria would make this patient platinum-ineligible?

RT @rafee_talukder
@TumorBoardTues @PGrivasMDPhD @MPishvaian @JohnEbbenMDPhD @MattGalsky @DrRosenbergMSK @JonAnker1 6/19 #TumorBoardTuesday

What thresholds should be used to define platinum ineligibility in #UrothelialCancer?
@shilpaonc Defining platinum-ineligible in patients with metastatic urothelial cancer
📚https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.4577